Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
16.57M | 33.20M | 45.89M | 35.27M | 31.34M | 28.74M | Gross Profit |
3.63M | 6.78M | 11.29M | 10.52M | 8.59M | 5.85M | EBIT |
-9.27M | -11.35M | -10.42M | -5.36M | 1.18M | 1.67M | EBITDA |
-3.02M | -4.10M | -5.96M | -3.94M | 1.98M | 2.45M | Net Income Common Stockholders |
-9.95M | -12.34M | -9.61M | -5.95M | 2.35M | 1.17M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
974.83K | 1.23M | 1.34M | 1.77M | 1.40M | 974.83K | Total Assets |
0.00 | 10.05M | 20.76M | 24.61M | 11.11M | 8.25M | Total Debt |
0.00 | 4.32M | 2.41M | 3.45M | 754.40K | 0.00 | Net Debt |
974.83K | 3.08M | 1.07M | 1.68M | -648.30K | -974.83K | Total Liabilities |
0.00 | 9.51M | 8.38M | 8.48M | 6.78M | 6.28M | Stockholders Equity |
1.97M | 538.00K | 12.39M | 16.13M | 4.33M | 1.97M |
Cash Flow | Free Cash Flow | ||||
938.00K | -1.63M | -5.92M | -10.42M | -1.21M | 318.86K | Operating Cash Flow |
944.00K | -1.61M | -2.60M | -7.29M | -734.67K | 3.97M | Investing Cash Flow |
-6.00K | -13.00K | -3.32M | -7.63M | -477.46K | -3.65M | Financing Cash Flow |
-985.00K | 1.52M | 5.49M | 15.29M | 1.64M | 0.00 |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
50 Neutral | $5.14B | 3.10 | -40.94% | 2.95% | 17.94% | 2.00% | |
45 Neutral | $3.05M | ― | -180.73% | ― | -100.00% | 5.43% | |
41 Neutral | $4.65M | ― | -178.39% | ― | 168.70% | 31.57% | |
31 Underperform | $2.60M | ― | 367.65% | ― | -100.00% | 69.07% | |
27 Underperform | $3.16M | ― | -49.77% | ― | ― | 71.41% | |
26 Underperform | $9.49M | ― | -292.41% | ― | -64.77% | 43.53% |
On April 10, 2025, Healthcare Triangle announced significant leadership changes with the resignation of CFO Thyagarajan Ramachandran and the appointment of David Ayanoglou as the new CFO. Ayanoglou brings over 23 years of corporate finance experience, notably in software M&A and financial reporting, which is expected to drive the company’s strategic growth. Additionally, Sujatha Ramesh was appointed as a Director on the Board, reinforcing the company’s commitment to operational excellence and digital innovation. Ramesh’s extensive experience in technology and financial services is anticipated to enhance the company’s leadership team as it continues its global expansion and transformation initiatives.
Spark’s Take on HCTI Stock
According to Spark, TipRanks’ AI Analyst, HCTI is a Underperform.
Healthcare Triangle is facing substantial financial challenges with negative revenue growth, persistent losses, and negative equity. The technical analysis indicates a bearish trend, with the stock trading below key moving averages. The lack of positive earnings and dividend yield further exacerbates the company’s weak position. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on HCTI stock, click here.